Sheridan joins independent journalist Nick Shirley to discuss how Nutriband's AVERSA™ abuse-deterrent technology is designed to help reduce the abuse, misuse, and accidental exposure driving the ongoing epidemicORLANDO, Fla., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that its CEO, Gareth Sheridan, has been featured in a new documentary by independent journalist and filmmaker Nick Shirley examining the ongoing opioid crisis in the United States.
ORLANDO, Fla., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO, Gareth Sheridan will attend the inaugural Nasdaq LaB Biotech Summit on September 16th. The Summit brings together biotechnology executives, investors, and industry leaders for an evening of thought leadership and networking at Nasdaq MarketSite in New York. About AVERSA™ Abuse-Deterrent Transdermal Technology Nutriband's AVERSA™ abuse-deterrent transdermal technology incorp
Nutriband has received a Notice of Publication from the United States Patent and Trademark Office (USPTO) for commercial brand name trademarks for its lead product, an abuse deterrent fentanyl transdermal system. Once allowed, Nutriband plans to submit its commercial worldwide brand name to the FDA and other international regulatory agencies for approval. ORLANDO, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescrip
This is the newest page. Registered accounts read further back.